Single probit model | Bivariate probit model | |||
---|---|---|---|---|
Marginal effect (95% C.I.) | Marginal effect (95% C.I.) | |||
Age | -0.004** | (-0.006, -0.003) | -0.003** | (-0.004, -0.002) |
Gender (female) | -0.014 | (-0.046, 0.018 ) | -0.010 | (-0.033, 0.014) |
mRS pre-admission | ||||
mRS = 0 | - | - | - | |
mRS = 1 | -0.055** | (-0.092, -0.019) | -0.041** | (-0.068, -0.014) |
mRS = 2 | -0.329** | (-0.357, -0.301) | -0.220** | (-0.248, -0.192) |
mRS = 3 | -0.384** | (-0.406, -0.361) | -0.257** | (-0.287, -0.226) |
Functional severity score¶ | -0.216** | (-0.228, -0.204) | -0.155** | (-0.168, -0.142) |
Functional capability score¶ | 0.089** | (0.073, 0.104 ) | 0.053** | (0.041, 0.065) |
Co-morbidity index (CI > 2) | -0.017 | (-0.047, 0.014) | -0.010 | (-0.033, 0.013) |
Use of edaravone | -0.013 | (-0.044, 0.018 ) | -0.009 | (-0.031, 0.013) |
VEI | 0.048** | (0.013, 0.084 ) | 0.153** | (0.072, 0.234) |
Training intensity | -0.015* | (-0.029, -0.002) | -0.011* | (-0.020, -0.001) |
First stage regression | ||||
Friday admission | -0.076** | (-0.092, -0.059) |